News und Analysen

AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations, has scheduled a conference call to discuss its first quarter 2021

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2021 on Thursday, April 29, 2021, before the U.S. financial markets open. Novocure’s management

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Retrogenix Limited, an early-stage contract research organization (CRO) providing specialized

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Geisinger Health, one of Pennsylvania’s premier, integrated healthcare systems. The new

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005652/en/

Vifor Fresenius Medical Care Renal Pharma (VFMCRP)

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc. for approximately $875 million

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Emergency Use Authorization by the U.S. FDA for the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Assay that will help

Regulatory News:

Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021.

Åsa Riisberg, a

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Lutheran Health Network of Indiana, LLC, one of Indiana’s premier, integrated healthcare

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2021 results on Wednesday, April 28, 2021 at 12 p.m

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 3.750% senior

Recordati Rare Diseases gibt bekannt, dass positive Ergebnisse aus der Phase-III-Studie LINC 4 zu Isturisa® am 22. März auf der Jahrestagung der Endocrine Society präsentiert wurden.¹

Ergebnisse

Recordati Rare Diseases announces that positive results from the Phase III LINC 4 study of Isturisa® were presented on March 22 at The Endocrine Society’s Annual Meeting.¹

Results from LINC 4

The most potentially disruptive forces facing hospitals and health systems in the next three years are provider burnout, disengagement, and resulting shortages among healthcare professionals

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that members of its management team are scheduled to present at the KeyBanc Capital Markets Virtual Life

Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 31^st Annual Healthcare Conference on Wednesday, March 17, 2021, at approximately 8:40

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today

ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health

Charles River Laboratories International, Inc. (NYSE: CRL) announced that on March 8, 2021 it priced its private offering (the “offering”) of $500 million in aggregate principal amount of 3.750%

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $1 billion aggregate principal amount of senior notes due 2029 and 2031 (the “notes”) in an

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Barclays Global Healthcare Conference on Wednesday, March 10^th, at 10:20 a.m. ET

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210307005039/en/

Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat die cloudbasierte Plattform QIAsphere auf den Markt gebracht, mit der Labore und QIAstat-Dx-Anwender rund um die Uhr und ortsunabhängig Tests

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours